A novel delivery platform for therapeutic peptides

Area of Science:

• Pharmacology and Drug Delivery
• Biotechnology
• Medicinal Chemistry

Background:

• Therapeutic peptides demonstrate potential for treating various diseases.
• Short in vivo half-lives limit the clinical application of many peptide drugs.
• Need for innovative strategies to enhance peptide drug stability and duration of action.

Purpose of the Study:

• To develop and evaluate a novel peptide delivery platform for extending in vivo half-lives.
• To utilize an anti-hapten antibody and its corresponding hapten for peptide stabilization.
• To assess the therapeutic efficacy of a modified peptide using this delivery system.

Main Methods:

• Development of a delivery platform based on an anti-hapten antibody and a selected hapten (cotinine).
• Conjugation of the anti-sepsis therapeutic peptide WKYMVm-NH2 to cotinine.
• Evaluation of the in vivo half-life and therapeutic efficacy of the cotinine-conjugated peptide in complex with an anti-cotinine antibody.

Main Results:

• The cotinine-conjugated peptide, when complexed with an anti-cotinine antibody, exhibited a significantly prolonged in vivo half-life.
• The therapeutic efficacy of the peptide was successfully retained after conjugation and complex formation.
• Demonstrated the feasibility of the hapten-antibody system for peptide drug delivery.

Conclusions:

• The novel hapten-antibody based delivery platform effectively extends the half-life of therapeutic peptides.
• This approach maintains the therapeutic efficacy of the modified peptides.
• The developed platform holds significant promise for the advancement of peptide-based therapeutics.